IDEXX Laboratories, Inc. (NASDAQ:IDXX) Given Consensus Rating of "Moderate Buy" by Analysts

IDEXX Laboratories, Inc. (NASDAQ:IDXX - Get Free Report) has been given a consensus rating of "Moderate Buy" by the ten brokerages that are presently covering the company, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $533.75.

Several equities analysts have recently weighed in on IDXX shares. Barclays lifted their target price on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 4th. Bank of America increased their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a research report on Tuesday, February 4th. StockNews.com upgraded IDEXX Laboratories from a "hold" rating to a "buy" rating in a research report on Friday. Piper Sandler raised their price objective on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a research report on Monday, February 10th. Finally, Morgan Stanley reduced their price target on shares of IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating for the company in a research report on Wednesday, January 29th.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the transaction, the director now directly owns 3,061 shares of the company's stock, valued at approximately $1,426,242.34. This trade represents a 49.50 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP George Fennell sold 9,986 shares of the company's stock in a transaction on Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the sale, the executive vice president now directly owns 8,176 shares of the company's stock, valued at $3,781,645.28. This trade represents a 54.98 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 2.11% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of IDXX. FMR LLC grew its position in IDEXX Laboratories by 3.6% during the 3rd quarter. FMR LLC now owns 290,861 shares of the company's stock worth $146,949,000 after acquiring an additional 10,017 shares during the last quarter. Quantbot Technologies LP bought a new stake in IDEXX Laboratories during the 3rd quarter valued at $341,000. Public Sector Pension Investment Board raised its holdings in IDEXX Laboratories by 16.2% during the 3rd quarter. Public Sector Pension Investment Board now owns 3,578 shares of the company's stock valued at $1,808,000 after buying an additional 500 shares during the last quarter. Verition Fund Management LLC boosted its position in IDEXX Laboratories by 20.5% during the 3rd quarter. Verition Fund Management LLC now owns 6,508 shares of the company's stock valued at $3,288,000 after buying an additional 1,108 shares during the period. Finally, Erste Asset Management GmbH bought a new stake in IDEXX Laboratories in the 3rd quarter worth $1,428,000. 87.84% of the stock is owned by institutional investors.

IDEXX Laboratories Stock Performance

IDXX stock traded down $14.74 during mid-day trading on Thursday, hitting $378.99. The company had a trading volume of 1,818,009 shares, compared to its average volume of 597,812. The stock's fifty day moving average price is $434.58 and its two-hundred day moving average price is $438.33. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31. IDEXX Laboratories has a 12 month low of $365.93 and a 12 month high of $548.88. The firm has a market cap of $30.71 billion, a PE ratio of 35.52, a price-to-earnings-growth ratio of 3.41 and a beta of 1.50.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.